Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $674K | $4.58M | $3.60M | $443K | $21.0M | $931K | $477K | $424K | $501K | $570K |
| Revenue growth | — | 579.8% | -21.5% | -87.7% | 4638.8% | -95.6% | -48.8% | -11.1% | 18.2% | 13.8% |
| Operating income | -$14.3M | -$29.6M | -$74.9M | -$95.9M | -$253M | -$38.9M | -$34.3M | -$29.3M | -$43.6M | -$29.7M |
| Operating margin | -2126.4% | -645.9% | -2083.2% | -21641.8% | -1203.0% | -4179.5% | -7189.7% | -6900.5% | -8710.0% | -5219.1% |
| Net income | -$14.1M | -$29.1M | -$74.2M | -$95.2M | -$256M | -$73.3M | -$23.2M | -$28.5M | -$39.8M | -$26.5M |
| Net margin | -2087.2% | -634.6% | -2062.9% | -21484.9% | -1217.4% | -7876.4% | -4865.8% | -6710.4% | -7950.9% | -4646.1% |
| EPS (diluted) | -$2.82 | -$5.69 | $11.47 | $11.22 | $7.88 | -$25.64 | -$7.28 | -$2.78 | -$0.93 | -$0.62 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.27M | -$28.2M | -$68.7M | -$73.4M | -$137M | -$56.4M | -$29.2M | -$25.3M | -$34.0M | -$33.1M |
| Capital expenditures | $31.0K | $27.0K | $567K | $1.06M | $113K | $0.00 | — | $0.00 | $117K | $0.00 |
| Free cash flow | -$2.30M | -$28.2M | -$69.2M | -$74.5M | -$137M | -$56.4M | — | -$25.3M | -$34.1M | -$33.1M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.03M | $10.2M | $27.9M | $43.8M | $57.6M | $42.3M | $30.9M | $30.6M | $19.9M | $24.0M |
| Total assets | $42.1M | $66.9M | $140M | $81.2M | $93.7M | $67.0M | $40.8M | $97.7M | $66.9M | $30.2M |
| Total liabilities | $12.5M | $14.6M | $9.55M | $63.6M | $56.2M | $18.4M | $9.35M | $8.95M | $14.8M | $2.40M |
| Long-term debt | — | — | — | $32.7M | $33.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shareholders' equity | -$29.4M | $68.6M | $92.2M | $17.6M | $37.5M | $48.6M | $31.2M | $88.7M | $52.1M | $27.8M |
| Retained earnings | -$30.1M | -$59.2M | -$111M | -$311M | -$566M | -$640M | -$663M | -$691M | -$731M | -$758M |
| Shares (wtd avg diluted) | 5.28M | 5.30M | 23.2M | 9.12M | 32.4M | 2.86M | 3.19M | 10.3M | 42.6M | 42.8M |
Every figure is extracted from VYNE Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.